Alzheimer’s Drugs Keep Slowing Cognitive Decline After 3 to 4 Years
New long-term data suggests anti-amyloid monoclonal antibody (mAb) drugs — including lecanemab (Leqembi) and donanemab (Ki...
Continue with Facebook
Sign up with your email
Become a member to get even more